Steven E. Nissen

Steven E Nissen

Cleveland Clinic, Cleveland, US


Dr. Steven E. Nissen, an esteemed American cardiologist, researcher, and patient advocate, has left an indelible mark in the field of cardiology. Formerly the chairman of cardiovascular medicine at the renowned Cleveland Clinic in Ohio, Dr. Nissen brings a wealth of experience and expertise to his roles.

Joining the Cleveland Clinic in 1992, Dr. Nissen held key positions, including Vice-Chairman of the Department of Cardiology, Section Head of Clinical Cardiology, and Director of the Coronary Intensive Care Unit. In his most recent role, he served as the Medical Director of the Cleveland Clinic Cardiovascular Coordinating Center (C5), overseeing multi-center clinical trials. Dr. Nissen continues to contribute periodically in the Cardiac Critical Care Unit, showcasing his ongoing commitment to patient care.

A highly accomplished academic, Dr. Nissen graduated from the Webb School of California before pursuing his undergraduate degree at the University of Michigan. He earned his medical degree from the University of Michigan School of Medicine in Ann Arbor and completed his internal medicine internship and residency at the University of California, Davis, followed by a cardiology fellowship at the University of Kentucky Medical Center in Lexington.

Dr. Nissen's groundbreaking work in imaging technology, particularly producing the first images in humans in 1990, has been foundational in documenting the widespread prevalence of coronary artery disease. His current role as the principal investigator for several large IVUS atherosclerosis trials underscores his commitment to advancing cardiovascular research.

As a staunch advocate for scientific integrity in medications, Dr. Nissen has led inquiries into various medications on the market. Notably, his early association of COX-2 inhibitors, such as Vioxx, with an increased risk of heart attacks and strokes, led to significant changes in drug usage. His meticulous analysis of data related to drugs like Pargluva and rosiglitazone (Avandia) has had profound implications for drug safety and usage.

Dr. Nissen's impactful research includes leading studies on ApoA-I Milano/phospholipids complex, demonstrating its potential in removing plaque from coronary arteries. His pivotal role in the REVERSAL trial highlighted the importance of lowering LDL cholesterol levels in halting plaque progression.

Recognized globally for his contributions, Dr. Nissen was named one of the 100 Most Influential People in the World by Time Magazine in 2007. He has received numerous awards, including the Outstanding Teacher Award by the Cleveland Clinic Fellows in Cardiovascular Medicine and the Gill Heart Institute Award of the University of Kentucky for Outstanding Contributions to Cardiovascular Research.

With over 350 journal articles and book chapters to his name, predominantly in cardiovascular imaging, Dr. Nissen's impact extends to his editorial roles, including Editorship of Current Cardiology Report and Senior Consulting Editor to the Journal of the American College of Cardiology.

Dr. Nissen's dedication to advancing cardiovascular knowledge and patient advocacy continues to shape the landscape of cardiology, making him a prominent figure in the field.